OBJECTIVE: To determine whether omega-3 fatty acid (FA) increases the natural log of very low frequency (lnVLF) power, an index of heart rate variability (HRV), and reduces 24-hour heart rate (HR) in depressed patients with coronary heart disease (CHD). Low intake of omega-3 FAs is associated with depression and with low HRV, and all three are associated with an increased risk of death in patients with CHD. METHODS:Thirty-six depressed patients with CHD randomized to receive 50 mg of sertraline and 2 g of omega-3/day, and 36 randomized to sertraline and a placebo, had 24-hour HRV measured at baseline and after 10 weeks of treatment. RESULTS: There was a significant treatment × time interaction for covariate adjusted lnVLF (p = .009), for mean 24-hour HR (p = .03), and for 1-minute resting HR (p = .02). The interaction was not significant for three other measures of HRV. LnVLF did not change over time in the omega-3 arm but decreased in the placebo arm (p = .002), suggesting that omega-3 may have prevented or slowed deterioration in cardiac autonomic function. CONCLUSIONS: The effects of omega-3 FAs on lnVLF and HR, although modest, were detected after only 10 weeks of treatment with 2 g per day of omega-3. Whether a longer course of treatment or a higher dose of omega-3 would further decrease HR, improve other indices of HRV, or reduce mortality in depressed CHD patients should be investigated.
RCT Entities:
OBJECTIVE: To determine whether omega-3 fatty acid (FA) increases the natural log of very low frequency (lnVLF) power, an index of heart rate variability (HRV), and reduces 24-hour heart rate (HR) in depressedpatients with coronary heart disease (CHD). Low intake of omega-3 FAs is associated with depression and with low HRV, and all three are associated with an increased risk of death in patients with CHD. METHODS: Thirty-six depressedpatients with CHD randomized to receive 50 mg of sertraline and 2 g of omega-3/day, and 36 randomized to sertraline and a placebo, had 24-hour HRV measured at baseline and after 10 weeks of treatment. RESULTS: There was a significant treatment × time interaction for covariate adjusted lnVLF (p = .009), for mean 24-hour HR (p = .03), and for 1-minute resting HR (p = .02). The interaction was not significant for three other measures of HRV. LnVLF did not change over time in the omega-3 arm but decreased in the placebo arm (p = .002), suggesting that omega-3 may have prevented or slowed deterioration in cardiac autonomic function. CONCLUSIONS: The effects of omega-3 FAs on lnVLF and HR, although modest, were detected after only 10 weeks of treatment with 2 g per day of omega-3. Whether a longer course of treatment or a higher dose of omega-3 would further decrease HR, improve other indices of HRV, or reduce mortality in depressed CHDpatients should be investigated.
Authors: Kenneth E Freedland; Judith A Skala; Robert M Carney; James M Raczynski; C Barr Taylor; Carlos F Mendes de Leon; Gail Ironson; Marston E Youngblood; K Ranga Rama Krishnan; Richard C Veith Journal: Psychosom Med Date: 2002 Nov-Dec Impact factor: 4.312
Authors: Janice K Kiecolt-Glaser; Martha A Belury; Kyle Porter; David Q Beversdorf; Stanley Lemeshow; Ronald Glaser Journal: Psychosom Med Date: 2007-03-30 Impact factor: 4.312
Authors: R M Carney; J A Blumenthal; P K Stein; L Watkins; D Catellier; L F Berkman; S M Czajkowski; C O'Connor; P H Stone; K E Freedland Journal: Circulation Date: 2001-10-23 Impact factor: 29.690
Authors: Robert M Carney; Kenneth E Freedland; Eugene H Rubin; Michael W Rich; Brian C Steinmeyer; William S Harris Journal: J Clin Psychiatry Date: 2019-06-04 Impact factor: 4.384
Authors: Katherine A Sauder; Ann C Skulas-Ray; Tavis S Campbell; Jillian A Johnson; Penny M Kris-Etherton; Sheila G West Journal: Psychosom Med Date: 2013-04-16 Impact factor: 4.312
Authors: Robert M Carney; Brian C Steinmeyer; Kenneth E Freedland; Eugene H Rubin; Michael W Rich; William S Harris Journal: J Clin Psychiatry Date: 2016-02 Impact factor: 4.384
Authors: Wendy L Hall; Georgia Hay; Zoitsa Maniou; Paul T Seed; Philip J Chowienczyk; Thomas A B Sanders Journal: Int J Cardiol Date: 2013-07-26 Impact factor: 4.164